| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Completed merger with Cyclerion Therapeutics and concurrent $380 million private placement |
| 11 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +9 more
Includes related party amount of $5,751 as of June 30, 2026 and $10,565 as of December 31, 2025 (see Note 13). |
| 27 Aug 2026 |
8-K: Submission of Matters to a Vote of Security Holders; Other Events
In connection with the Merger, Cyclerion held an annual meeting of Cyclerion shareholders on August 26, 2026 (the “Shareholder Meeting”), at which the Company’s shareholders voted on the proposals set forth below relating to the Merger A... |
| 25 Aug 2026 |
8-K: Other Events
On August 25, 2026, the board of directors of Cyclerion Therapeutics, Inc. (the “Company”) fixed the close of business on September 4, 2026 as the record date for the Company’s previously announced distribution (the “CVR Distribution”) o... |
| 01 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Changes in Control of Registrant +2 more
First Certificate of Merger, including certificate of incorporation of the First Step Surviving Corporation attached as Exhibit A thereto, incorporated by reference into this Agreement |
| 17 Feb 2026 |
8-K: Regulation FD Disclosure
–Received Positive Pre-Investigational New Drug (“IND”) Written Feedback from the U.S. Food and Drug Administration (“FDA”)– |
| 06 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Exhibit 99.2 Cyclerion: Pioneering a New Era in Neuropsychiatric Therapies th Investor Call: January 6 , 2026 |
| 01 Dec 2025 |
8-K: Other Events
On December 1, 2025, Akebia Therapeutics, Inc. (“Akebia”) publicly announced that it has recently initiated Phase 2 clinical trials for the treatment of focal segmental glomerulosclerosis (“FSGS”) using Praliciguat, an oral soluble guany... |
| 23 Sep 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Exhibit 99.2 Cyclerion: Pioneering a New Era in Neuropsychiatric Therapies Investor Call th September 24 , 2025, 10:30am EST |
| 18 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
At the Annual Meeting of Shareholders of Cyclerion Therapeutics, Inc. (the “Company”) held on June 16, 2025, as contemplated by the Company’s definitive proxy material for the meeting, certain matters were submitted to a vote of sharehol... |
| 07 May 2025 |
8-K: Entry into a Material Definitive Agreement
Cyclerion Therapeutics, Inc., a Massachusetts corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Guggenheim Securities, LLC, as sales agent and/or princip... |
| 25 Mar 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
This STOCK PURCHASE AGREEMENT (this “Agreement”) is dated as of March 21, 2025, by and among Cyclerion Therapeutics, Inc., a Massachusetts corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreeme... |
| 17 Dec 2024 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Certain information has been excluded from this agreement (indicated by “[***]”) because such information is both not material and the type that the registrant treats as private or confidential. |
| 07 Aug 2024 |
8-K: Regulation FD Disclosure
CAMBRIDGE, Mass., August 7, 2024 – Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced that Regina Graul, Ph.D., has been promoted to Chief Executive Officer, President, and member of the Board of Directors. Since Dr. Graul join... |
| 14 Jun 2024 |
8-K: Submission of Matters to a Vote of Security Holders
At the Company’s Annual Meeting of Shareholders held on June 14, 2024, as contemplated by the Company’s definitive proxy material for the meeting, certain matters were submitted to a vote of shareholders. The following tables summarize t... |
| 18 Apr 2024 |
8-K: Other Events
On April 18, 2024, Cyclerion Therapeutics, Inc. (the “Company”) announced that the date for its 2024 Annual Meeting of Shareholders (the “2024 Annual Meeting”) has been established as June 14, 2024 and will be held via virtual format. Th... |
| 04 Dec 2023 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy – |
| 01 Dec 2023 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
- Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurological and psychiatric disorders |
| 24 Nov 2023 |
8-K: Departure/Election of Directors or Officers; Compensation
On November 19, 2023, Ole Isacson, M.D., Ph.D., tendered his resignation as a director of Cyclerion Therapeutics, Inc. (the “Company”), effective immediately. Dr. Isacson served as Chair of the Compensation Committee and a member of the ... |
| 23 Oct 2023 |
8-K: Departure/Election of Directors or Officers; Compensation
This Separation and Release of Claims Agreement (“Agreement”), dated as of October 17, 2023, is entered into by and between Cyclerion Therapeutics, Inc. and its successors and assigns (the “Employer”) and Anjeza Gjino (the “Employee”) (t... |
Loading...